Furthermore, according to a more recent work reported by Kontzias et al., canakinumab, a fully human monoclonal antibody against IL-1β with a long half-life, successfully controlled disease flares in AOSD patients refractory to DMARDs, anakinra (short-acting IL-1 blockade), and rilonacept (moderate-acting IL-1 blockade). Here, IL1B is linked to adult-onset Still disease.